+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2020

  • ID: 5007699
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 1202 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Cadila Healthcare Ltd
  • GB Sciences Inc
  • Laboratory Biodim
  • OyaGen Inc
  • Taiga Biotechnologies Inc
  • MORE
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2020, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 14, 48, 47, 1, 6, 102, 64 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 3, 15, 28, 49 and 66 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Cadila Healthcare Ltd
  • GB Sciences Inc
  • Laboratory Biodim
  • OyaGen Inc
  • Taiga Biotechnologies Inc
  • MORE
  • Introduction
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by 2A Pharma AB, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AbbVie Inc, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Actinobac Biomed Inc, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2020
  • Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 2A Pharma AB
  • AbbVie Inc
  • Abivax SA
  • Actinobac Biomed Inc
  • AdAlta Ltd
  • Advanced Genetic Systems Inc
  • Aelix Therapeutics SL
  • AIM ImmunoTech Inc
  • Akshaya Bio Inc
  • AlbaJuna Therapeutics
  • Altor Bioscience LLC
  • American Gene Technologies International Inc
  • Aphios Corp
  • Apimeds Inc
  • Atreca Inc
  • AUM LifeTech Inc
  • Auritec Pharmaceuticals Inc
  • Avixgen Inc
  • B Cell Design SAS
  • Biological Mimetics Inc
  • Bionor Holding AS
  • BioNTech SE
  • Biosantech SA
  • Biotron Ltd
  • Bolder Biotechnology Inc
  • Brandenburg Antiinfektiva GmbH
  • Bristol-Myers Squibb Co
  • BryoLogyx Inc
  • Bukwang Pharm Co Ltd
  • Cadila Healthcare Ltd
  • Califia Bio Inc
  • Celdara Medical LLC
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Chipscreen Biosciences Ltd
  • Cidara Therapeutics Inc
  • Clover Biopharmaceuticals
  • Cocrystal Pharma Inc
  • Collaborations Pharmaceuticals Inc
  • Consegna Pharma Inc
  • CSL Ltd
  • Curevac AG
  • Cytocom Inc
  • Cytodyn Inc
  • CytRx Corp
  • DFH Pharma Inc
  • Diaccurate
  • E-Vaccines Inc
  • Emergent BioSolutions Inc
  • Emmune Inc
  • Enochian Biosciences Inc
  • Enzo Biochem Inc
  • EpiVax Inc
  • eTheRNA Immunotherapies NV
  • Evotec SE
  • Excision BioTherapeutics Inc
  • ExQor Technologies Inc
  • FIT Biotech Oy (Inactive)
  • Fox Chase Chemical Diversity Center Inc
  • Frontier Biotechnologies Inc
  • Fujifilm Toyama Chemical Co Ltd
  • GB Sciences Inc
  • GeneCure LLC
  • Genetic Immunity Inc
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • Globeimmune Inc
  • Greffex Inc
  • GT Biopharma Inc
  • Helocyte Biosciences Inc
  • Henan Zhenshi Biotechnology Co Ltd
  • Hepion Pharmaceuticals Inc
  • Hetero Drugs Ltd
  • Hoverink Biotechnologies Inc
  • iCo Therapeutics Inc
  • ID Pharma Co Ltd
  • IGXBio Inc
  • Immune Modulation Inc
  • Immune Response BioPharma Inc
  • Immunologik GmbH
  • Immunotope Inc
  • ImQuest Life Sciences Inc
  • Innovare R & D SA De CV
  • Inovio Pharmaceuticals Inc
  • Intarcia Therapeutics Inc
  • Intrucept Biomedicine LLC
  • InvVax Inc
  • ISR Immune System Regulation Holding AB
  • Jericho Sciences LLC
  • Jiangsu Aidea Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Kainos Medicine Inc
  • Kanglin Biotech Hangzhou Co Ltd
  • Karyopharm Therapeutics Inc
  • Kymab Ltd
  • Laboratory Biodim
  • Lauren Sciences LLC
  • Longevity Biotech Inc
  • Looove Biotechnology Beijing Co Ltd
  • Lyndra Inc
  • MacroGenics Inc
  • Mapp Biopharmaceutical Inc
  • Merck & Co Inc
  • Miltenyi Biotec GmbH
  • Minka Therapeutics SA
  • Molecular Express Inc
  • Mologen AG
  • Mutabilis SA
  • Mycenax Biotech Inc
  • Mymetics Corp
  • NanoViricides Inc
  • Navigen Inc
  • NeED Pharma srl
  • New World Laboratories Inc
  • NovalGen Ltd
  • Novodux
  • Omeros Corp
  • Oncologie Inc
  • Oncolys BioPharma Inc
  • Oncotelic Inc
  • Oncovir Inc
  • Orbis Biosciences Inc
  • Orion Biotechnology Canada Ltd
  • Osel Inc
  • OyaGen Inc
  • Palisades Therapeutics
  • Pepscan Therapeutics BV
  • Phoenix Biotechnology Inc
  • PlantForm Corp
  • Polyrizon Ltd
  • Profectus BioSciences Inc
  • Protheragen Inc
  • ReceptoPharm Inc
  • Recombio SL
  • Repair Biotechnologies Inc
  • Resverlogix Corp
  • RetroVirox Inc
  • Rodos BioTarget GmbH
  • Samjin Pharm Co Ltd
  • Sangamo Therapeutics Inc
  • Savoy Pharmaceuticals Inc
  • Secura Bio Inc
  • Serum Institute of India Ltd
  • Shanghai Pharmaceutical Group Co Ltd
  • Shionogi & Co Ltd
  • SignalRx Pharmaceuticals Inc
  • Sirga Advanced Biopharma Inc
  • SMET Pharmaceutical Inc
  • ST Pharm Co Ltd
  • Staidson BioPharma Inc
  • Starpharma Holdings Ltd
  • Sumagen Co Ltd
  • Sunomix Therapeutics
  • Susavion Biosciences Inc
  • Taiga Biotechnologies Inc
  • TaiMed Biologics Inc
  • Takara Bio Inc
  • Takeda Pharmaceutical Co Ltd
  • Targeted Pharmaceuticals LLC
  • TechnoVax Inc
  • TeneoBio Inc
  • Tetranov International Inc
  • TGV Laboratories Inc
  • TheraJect Inc
  • Theratechnologies Inc
  • Theravectys SA
  • Transgene Biotek Ltd
  • TVAX Biomedical Inc
  • United Biomedical Inc
  • Vaccibody AS
  • Vault Pharma Inc
  • VG Life Sciences Inc
  • Vichem Chemie Research Ltd
  • ViiV Healthcare UK Ltd
  • Vincogen Corp
  • Vir Biotechnology Inc
  • Viramatix Sdn Bhd
  • Viravaxx AG
  • Viriom Inc
  • ViroStatics SRL
  • ViroXis SAS
  • Winsantor Inc
  • XL-protein GmbH
  • Xyphos Biosciences Inc
  • Yaso Therapeutics Inc
  • Yisheng Biopharma Co Ltd
  • Zata Pharmaceuticals Inc
  • Zion Medical
Note: Product cover images may vary from those shown
Adroll
adroll